Suppliers / Bliss GVS Pharma

Bliss GVS Pharma

India 2 duplicate records merged Updated 9 July 2026

Bliss GVS Pharma is a finished-dose manufacturer based in India. It appears in 165 regulatory filings across 14 regulators, without an active US DMF or CEP on file. Its filings concentrate with ZAMRA (ZM), NAFDAC (NG) and TMDA (TZ). Its GMP standing is certified by CDSCO (India), TMDA (TZ) and FDA (GH), among 5 authorities. Its most recent recorded inspection, by US FDA, closed on 17 March 2023 as VAI. Customs aggregates show $65.5M of exports covering 2,638 molecules to 56 destinations in 2025.

0
active US DMFs
0
valid CEPs
7
registered plants 2 with an FDA FEI number
165
filings across 14 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
1 of 1 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 17 March 2023 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Maharashtra, United Arab Emirates Not on file
Palghar, India 3007068506
Palghar, India 3008380269
vapivapi 396 195 valsad, India Not on file
ay stationvillage ranoli 391 350vadodara, India Not on file
G.I.D.C., India Not on file

1 further sites are on record.

Filings and GMP by regulator

Regulator Filings GMP certificates
ZAMRA (ZM) 51 None
NAFDAC (NG) 31 1
TMDA (TZ) 21 2
FDA (GH) 18 2
MINSA (CR) 11 None
DAV (Vietnam) 10 None
CDSCO (India) None 4
EMA None 1

Scale

Year Revenue Exports Destinations
2025 Not reported $65.5M 56
2024 Not reported $74.2M 52
2023 Not reported $69.0M 58
2022 Not reported $69.8M 53

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Bliss GVS Pharma comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 17 March 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts